Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix
Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix
Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix
Submitted by
admin
on October 30, 2021 - 10:50pm
Source:
Motley Fool
News Tags:
Pfizer
Chantix
dry eye disease
Oyster Point Pharma
Headline:
Why Pfizer Isn't the Big Winner With a Newly Approved Version of Chantix
snippet:
The FDA recently approved a version of smoking cessation drug Chantix to treat dry eye disease.
Oyster Point Pharma will market the drug in this new indication after licensing it from Pfizer.
Do Not Allow Advertisers to Use My Personal information
